|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | USB data acquisition solution显示文摘 | Serges Lemo Zhu June | 2007 | 国外电子测量技术2007，26，2： | 2 |
| 2 | A high performance electrochemical sensor for acetaminophen based on single-walled carbon nanotube-graphene nanosheet hybrid films显示文摘 | Xu Chen June Zhu Qian Xi | 2012 | Sensors and Actuators B2012，161，： | 1 |
| 3 | A high performance electrochemical sensor for acetanlinophen based on single-walled carbon nanotube-graphene nanosheet hybrid films显示文摘 | CHEN Xu ZHU June XI Qian | 2012 | Sensors and Actuators B: Chemical2012，161，1： | 1 |
| 4 | Beyond virtual instrumentation显示文摘1 A Turning Point for Test and Measurement Instrumentation system has come a long way,in the early phase,it is represented by“pure”analog measure- ment devices,such as EEG recording system or oscillo- scope.They were completely closed dedicated systems, which included power supply,sensors,analog to | June Zhu | 2007 | 国外电子测量技术2007，26，3： | 0 |
| 5 | Past,Present and Future of PXI显示文摘 | Xu Benny Zhu June | 2007 | 国外电子测量技术2007，26，1： | 0 |
| 6 | 浮生御温泉度假村显示文摘浮生御温泉度假村坐落在四川北部罗浮山脚下。四周有绿树环绕和寺庙点缀。这是一个由水塑造而成的场地。河流蜿蜒过村庄,还有来自地下热水井而自然溢出的温泉。这里是中国传统的温泉区域之一。从我们的项目一开始,这些迷人的风景就对设计的概念产生了强烈的影响。浮生御度假村一直是我们公司的一个特别的项目,他给了我们难得的机会来整合规划,建筑,景观和室内,塑造一个完整的基于土地,自然和水的概念。 | Wendy Saunders Vincent de Graaf German Roig Leonardo Colluci Allan Yin Claudia Juhre Zoe Zhu June Deng Andrew Irwin Shelley Mock Dongker Liat Goldman Toni Pavic Ted Zhang Jiaoyan | 2020 | 世界建筑导报2020，35，6： | 0 |
| 7 | A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations显示文摘Dear Editor,Uncommon mutations in exons 18-21 of the epidermal growth factor receptor(EGFR)gene account for 10%–15%of all EGFR mutations when considered as a whole group[1,2].However,each variant confers heterogeneous clinical outcomes to different generations of EGFR tyrosine kinase inhibitors(TKIs)with G719X,L861Q,and/or S768I showing adequate sensitivity to EGFR inhibition[1–3].Osimertinib,based on its superior survival outcomes,has become the preferred first-line treatment for patients diagnosed with advanced non-small cell lung cancer(NSCLC)harboring common EGFR mutations[4];however,its efficacy in patients harboring G719X,S768I,and/or L861Q mutations was comparable or even inferior to Afatinib[5].Afatinib,a second-generation EGFR-TKI,has received approval for extended clinical indication in treating previously untreated patients with metastatic NSCLC harboring G719X,L861Q,and/or S768I based on the findings from the pooled analysis of three clinical trials(LUX-Lung 2/3/6)[2].The real-world clinical efficacy of Afatinib for treating this patient subset has been consistently demonstrated by two large retrospective studies[6,7].In China,chemotherapy remains a standard first-line treatment for this patient subset,with Afatinib available only as an off-label treatment option. | Pingli Wang Liming Cao Panwen Tian Shengxiang Ren Liyun Miao Chengzhi Zhou Yun Fan Yuping Li Dongqing Lv Xin Zhao Mei Yang Chaonan Zhu Bing Yu June Xu Yong Song Kai Wang | 2023 | Cancer Communications2023，43，9： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员